10058-F4: Targeting c-Myc/Max Dimerization to Modulate TERT and Mitochondrial Apoptosis in Cancer Research

Introduction

The c-Myc oncoprotein is a central driver of cellular proliferation, metabolism, and survival in diverse cancer types. Its transcriptional activity relies on dimerization with Max, forming the c-Myc-Max heterodimer that binds E-box sequences across the genome to regulate gene expression. Aberrant c-Myc signaling promotes oncogenesis and therapy resistance, but direct pharmacological targeting of c-Myc has long been considered intractable due to its intrinsically disordered structure. 10058-F4 (SKU: A1169) has emerged as a groundbreaking small-molecule c-Myc-Max dimerization inhibitor, offering new leverage in apoptosis assay development and cancer pathway research.

This article provides an in-depth exploration of 10058-F4’s mechanism, its unique applications in modulating the c-Myc/Max heterodimer disruption pathway, and how it extends current knowledge by integrating recent discoveries in telomerase (TERT) regulation and mitochondrial apoptosis. Unlike prior reviews that primarily catalog functional outcomes or focus on assay techniques, here we critically examine how 10058-F4 enables precise mechanistic dissection of c-Myc-driven transcriptional programs with direct implications for acute myeloid leukemia research, prostate cancer xenograft modeling, and emerging DNA repair targets.

The c-Myc/Max Axis: A Central Hub in Oncogenic Signaling

c-Myc is a basic helix-loop-helix leucine zipper (bHLH-LZ) transcription factor that orchestrates a vast gene network encompassing cell cycle regulation, mitochondrial metabolism, and apoptotic pathways. Its activity is contingent upon heterodimerization with Max, enabling sequence-specific DNA binding and transcriptional activation. Disrupting the c-Myc-Max dimer undermines c-Myc’s oncogenic potential, making their interface an attractive therapeutic target.

While several reviews (see, for example, "10058-F4: Unraveling c-Myc/Max Disruption in Cancer and T...") have discussed the broader implications of c-Myc/Max inhibition for telomerase and DNA repair, our focus here is to dissect the molecular precision by which 10058-F4 disrupts these axes and the resulting downstream effects on apoptosis and stem cell gene regulation.

Mechanism of Action of 10058-F4: Selective c-Myc-Max Inhibition

10058-F4, chemically known as (5E)-5-[(4-ethylphenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one (MW: 249.35), is a cell-permeable, small-molecule c-Myc inhibitor that binds to the c-Myc bHLH-LZ domain. This interaction blocks c-Myc-Max heterodimer formation, precluding DNA binding and subsequent transcriptional activation of c-Myc target genes. The inhibitory effect is highly specific, as 10058-F4 does not disrupt other bHLH-LZ transcription factor interactions, thus minimizing off-target effects in apoptosis research and cancer biology studies.

Functionally, 10058-F4 treatment leads to a rapid decline in c-Myc mRNA and protein levels, culminating in cell cycle arrest and induction of apoptosis via the mitochondrial pathway. Mechanistically, this involves modulation of Bcl-2 family proteins, increased cytochrome C release, and the activation of caspases. In acute myeloid leukemia (AML) cell lines (e.g., HL-60, U937, NB-4), 10058-F4 induces apoptosis in a dose- and time-dependent manner, with pronounced effects at 100 μM after 72 hours. In vivo, intravenous administration in SCID mice with human prostate cancer xenografts (DU145, PC-3) results in measurable tumor growth inhibition, albeit with variable efficacy depending on tumor microenvironmental factors.

Chemical Properties, Formulation, and Handling of 10058-F4

10058-F4 is supplied as a solid and exhibits high solubility in DMSO (≥24.9 mg/mL) and moderate solubility in ethanol (≥2.64 mg/mL), but is insoluble in water. For optimal stability and activity, it should be stored at -20°C, and prepared solutions must be used promptly rather than stored long-term. These physicochemical characteristics position 10058-F4 as a robust tool for in vitro and in vivo studies requiring potent, selective c-Myc/Max heterodimer disruption.

Expanding the Mechanistic Horizon: c-Myc/Max Inhibition and TERT Regulation

A novel frontier in c-Myc inhibition research is the intersection with telomerase regulation, specifically the control of telomerase reverse transcriptase (TERT) expression. The recent study by Stern et al. (2024) elucidates the critical role of apurinic/apyrimidinic endodeoxyribonuclease 2 (APEX2) in promoting efficient TERT gene expression in human embryonic stem cells. Their findings reveal that APEX2 binding to repetitive MIR elements within TERT intron 2 is essential for optimal telomerase activity, highlighting a DNA repair–transcription nexus previously underappreciated in cancer and regenerative biology.

c-Myc is a well-established activator of TERT transcription, directly binding to E-box motifs in the TERT promoter. By leveraging 10058-F4 to selectively inhibit c-Myc/Max dimerization, researchers can now dissect the causative impact of c-Myc-driven TERT regulation, parse out contributions from DNA repair factors like APEX2, and model complex gene-environment interactions that underlie oncogenic immortality. This conceptual integration distinguishes our approach from existing articles, which primarily link c-Myc/Max disruption with telomerase activity in a correlative rather than mechanistic fashion.

Integration with Apoptosis and DNA Repair Pathways

10058-F4-induced c-Myc inhibition also triggers the mitochondrial apoptosis pathway—modulating Bcl-2 family proteins, promoting cytochrome C release, and activating caspases. This complements the emerging evidence that impaired TERT expression (due to compromised c-Myc/Max signaling or APEX2 deficiency) sensitizes cells to DNA damage and apoptotic stimuli (Stern et al., 2024). Thus, 10058-F4 serves as a versatile probe for studying the functional crosstalk between transcriptional control, DNA repair, and programmed cell death.

Comparative Analysis: 10058-F4 Versus Alternative Approaches

Previous content, such as "10058-F4: Advanced Applications of a c-Myc-Max Dimerizati...", has cataloged diverse c-Myc inhibitory strategies. However, many genetic or RNAi-based approaches (e.g., siRNA, CRISPR knockdown) lack the temporal precision and reversibility of small-molecule inhibitors. Peptide-based c-Myc inhibitors often suffer from poor cell permeability, limiting their utility in live-cell apoptosis assays. By contrast, 10058-F4’s cell-permeable structure and rapid pharmacodynamics allow for controlled, titratable modulation of c-Myc-driven transcription and downstream phenotypes in both 2D and 3D culture systems, as well as in vivo xenograft models.

Furthermore, while earlier studies (see "10058-F4: Deciphering c-Myc-Max Inhibition in Cancer and ...") have highlighted 10058-F4’s role in apoptosis assay development, our analysis goes further by elucidating the mechanistic underpinnings of c-Myc/Max inhibition in the regulation of TERT and mitochondrial apoptotic priming. This provides a multi-layered understanding relevant to both basic biologists and translational researchers.

Advanced Applications: From Acute Myeloid Leukemia to Prostate Cancer Xenografts

Acute Myeloid Leukemia Research

AML remains a formidable clinical challenge due to its heterogeneity and high relapse rates. c-Myc is frequently overexpressed in AML, driving proliferation and impeding differentiation. Using 10058-F4 to disrupt c-Myc/Max dimerization, researchers have induced robust, dose-dependent apoptosis in AML cell lines, marked by mitochondrial cytochrome C release and caspase activation. This highlights the potential utility of 10058-F4 as both a research tool and a candidate for preclinical combination therapy screening.

Prostate Cancer Xenograft Models

In vivo, 10058-F4 has demonstrated the ability to inhibit tumor growth in SCID mice bearing human prostate cancer xenografts (DU145, PC-3). While the efficacy varies with tumor context, these models enable the study of c-Myc-driven oncogenesis and apoptosis in a physiologically relevant setting. Researchers can utilize 10058-F4 to systematically probe the dependencies of tumor cells on c-Myc/Max signaling and to test combinatorial regimens with DNA-damaging agents or telomerase inhibitors.

Apoptosis Assay Development and Mitochondrial Pathways

10058-F4 is particularly valuable in apoptosis assay development, providing a means to selectively trigger the mitochondrial apoptosis pathway in c-Myc-dependent cells. This allows for high-throughput screening of apoptosis modulators and mechanistic dissection of Bcl-2 family protein dynamics. Notably, our approach builds upon but is distinct from prior surveys such as "10058-F4: Novel Insights into c-Myc Inhibition and Mitoch...", by directly linking c-Myc/Max inhibition to TERT regulation and DNA repair, rather than focusing solely on mitochondrial events.

Emerging Frontiers: c-Myc/Max, TERT, and Genome Stability

As underscored in the recent APEX2-TERT study (Stern et al., 2024), telomerase regulation is intimately tied to DNA repair mechanisms and repetitive DNA element stability. By integrating 10058-F4 into experimental designs, researchers can now parse the interconnected roles of c-Myc/Max dimerization, TERT transcriptional control, and the maintenance of genome integrity—opening new avenues for therapeutic targeting in cancer and age-related pathologies.

Conclusion and Future Outlook

10058-F4 stands at the forefront of small-molecule c-Myc inhibitors, uniquely enabling the study of c-Myc-Max dimerization in the context of apoptosis, telomerase regulation, and DNA repair. By providing temporal precision and mechanistic specificity, it empowers advanced research in acute myeloid leukemia, prostate cancer xenografts, and beyond. As our molecular understanding deepens—guided by integrative studies like Stern et al. (2024)—10058-F4 will remain an indispensable tool for unraveling the complexities of oncogenic signaling and developing next-generation therapeutic strategies.